MCPH1 And BRCA2 Cell Assay Results For PARP Inhibitor Sensitivity

Data underpinning a 2026 study comparing homologous recombination repair (HRR) deficiency and PARP-1 inhibitor sensitivity in MCPH1-deficient versus BRCA2-deficient human cells. Isobel G. Chapman generated this data to support figures in the associated publication. The dataset includes quantitative measurements from cell-based assays.

Use Cases

• Compare HRR activity levels between MCPH1-deficient and BRCA2-deficient cell lines using assay result columns.
• Correlate the magnitude of HRR defect (e.g., ~50% retained activity) with sensitivity metrics to specific PARP-1 inhibitors.
• Analyze the effect of MCPH1 co-depletion on PARP inhibitor sensitivity in BRCA2-deficient cells using comparative condition data.

Strengths

• Data directly supports peer-reviewed scientific conclusions on MCPH1 and BRCA2 function.
• Includes results for two clinically-relevant PARP-1 inhibitors.
• Published under a permissive CC-BY-4.0 license for reuse.

Limitations

• Very small dataset at 10.9 KB, indicating limited scope and likely few rows.
• Specific column names, row counts, and raw measurement values are not provided in the metadata.
• Data is specific to the experimental conditions of a single study, limiting generalizability.

Provenance

Source

Isobel G. Chapman, associated with a specific cancer biology research study.

Collection Method

Generated from cell-based assays measuring homologous recombination repair activity and drug sensitivity.

Freshness

Last updated in April 2026, indicating recent data.